Related Experiment Video
Updated: Jul 14, 2026
11:09
Generation of Aligned Functional Myocardial Tissue Through Microcontact Printing
Published on: March 19, 2013
Optimizing engineered heart tissue for therapeutic applications as surrogate heart muscle
Hiroshi Naito1, Ivan Melnychenko, Michael Didié
1Institute of Experimental and Clinical Pharmacology and Toxicology, University Medical Center Hamburg-Eppendorf, Martinistr. 5, 20246 Hamburg, Germany.
Circulation
|July 6, 2006
Summary
Engineered heart tissues (EHTs) using mixed cell populations and serum-free conditions show improved function and vascularization. Fusion of EHTs creates larger constructs for cardiac regeneration.
Area of Science:
- Biomedical Engineering
- Regenerative Medicine
- Cardiovascular Research
Background:
- Cardiac tissue engineering seeks to regenerate heart muscle.
- Current methods for engineered heart tissue (EHT) can be improved.
- Hypothesis: Enhanced EHTs via mixed cell populations, defined culture, and fusion.
Purpose of the Study:
- Improve engineered heart tissue (EHT) function and vascularization.
- Develop serum-free and Matrigel-free culture conditions for EHTs.
- Enable fusion of EHTs into larger, multi-unit constructs.
Main Methods:
- Constructed EHTs using native and myocyte-enriched heart cell populations.
- Developed peptide growth factor-supplemented, serum-free medium.
- Utilized triiodothyronine and insulin to eliminate Matrigel.
- Fused single-unit EHTs into multi-unit constructs.
Main Results:
- Native cell population EHTs exhibited superior contractile performance and vascularization.
- Serum-free conditions maintained contractile EHTs.
- Matrigel was successfully withdrawn from the reconstitution mixture.
- Multi-unit EHTs with variable geometries were formed via fusion.
Conclusions:
- Simulating native heart cell environments enhances EHT function and capillary formation.
- Primitive capillaries in EHTs may form an in vitro vascular bed for improved engraftment.
- Serum- and Matrigel-free conditions reduce EHT immunogenicity.
- EHT fusion enables the production of large constructs for cardiac regeneration.
Related Concept Videos
01:14Myocarditis III: Medical Management
Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
01:30Heart Failure V: Medical Management
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
01:22Heart Failure VI: Adjunct Therapies
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
01:30Cardiomyopathy II: Dilated Cardiomyopathy
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
01:29Cardiomyopathy III: Hypertrophic Cardiomyopathy
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
01:29Cardiomyopathy V: Interprofessional Care
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...